Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment.

• HPV infection is closely associated with the pathogenesis of Laryngeal papillomatosis. • Laryngeal papillomatosis recurrence can occur when latent HPV is activated. • Current surgical tools commonly used can't solve the latency and seeding of HPV. • Topical ALA-PDT can treat Laryngeal papillomatosis efficaciously and reduces tumor recurrence significantly. To explore the therapeutic effect of topical 5-Aminolevulinic Acid photodynamic therapy (ALA-PDT) on laryngeal papillomatosis (LP) treatment. 13 patients with LP underwent topical ALA-PDT after tumor resection (CO 2 laser or/and microdebrider resection). All patients were irradiated 3–4 times. After ALA-PDT treatment, the laryngoscopic examination was performed every 1–2 months to observe the therapeutic effect. All 13 patients were followed up for more than 1 year. Eleven cases (84.6%) showed no recurrence; two cases (15.4%) had relapses. One child developed III° inspiratory dyspnea caused by laryngeal mucosal edema and need endotracheal intubation again. Four patients had adhesion of the anterior commissure of the vocal cord. The detection rate of HPV infections was 76.9% and two patients had multiple HPV subtype co-infection. The preliminary effect of topical ALA-PDT significantly reduces recurrence and improves the cure rate of LP. Further research on this treatment is still required. [ABSTRACT FROM AUTHOR]